Atea Pharmaceuticals (AVIR) Stock Price Target 2026

The average analyst price target for Atea Pharmaceuticals is $8.50, 98.6% above the current price. The one analyst covering it rates it Outperform. Targets range from $7 to $10. The latest change came on Aug 13, 2026, when Morgan Stanley raised its price target on Atea Pharmaceuticals from $6 to $7 and kept an Equal-Weight rating.

The Average Analyst Price Target for Atea Pharmaceuticals is $8.50.

Price Target Range — 4 Quarters

Analyst Consensus — 1 Analysts

1Buy

Consensus RatingOutperform# Analysts1Avg. Consensus PT$8.50Upside to Avg. PT+98.6%

Rating Trend — Last 9 Months

Latest Upgrades and Downgrades for Atea Pharmaceuticals Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Aug 13, 2026	Morgan Stanley	Matthew Harrison	PT Raise	Equal-Weight	$6→$7
Mar 9, 2026	Evercore ISI Group	Jonathan Miller	PT Raise	Outperform	$6→$10
Apr 11, 2025	Morgan Stanley	Matthew Harrison	PT Cut	Equal-Weight	$6→$6
Aug 13, 2024	Morgan Stanley	Matthew Harrison	Upgrade	Underweight→Equal-Weight	$2→$7

Analyst Ratings News

PRO
Morgan Stanley Maintains Equal-Weight on Atea Pharmaceuticals, Raises Price Target to $7

Morgan Stanley analyst Matthew Harrison maintains Atea Pharmaceuticals (NASDAQ:AVIR) with a Equal-Weight and raises the price target from $6 to $7.

Benzinga Newsdesk

PRO
Evercore ISI Group Maintains Outperform on Atea Pharmaceuticals, Raises Price Target to $10

Evercore ISI Group analyst Jonathan Miller maintains Atea Pharmaceuticals (NASDAQ:AVIR) with a Outperform and raises the price target from $6 to $10.

Benzinga Newsdesk

PRO
Morgan Stanley Maintains Equal-Weight on Atea Pharmaceuticals, Lowers Price Target to $6

Morgan Stanley analyst Matthew Harrison maintains Atea Pharmaceuticals (NASDAQ:AVIR) with a Equal-Weight and lowers the price target from $6.2 to $6.

Benzinga Newsdesk

Atea Pharma Cuts Workforce By 25%, Expects $15 Million In Cost Savings, Plans Phase 3 Hepatitis C Trial

Atea Pharma posted a Q4 loss of $0.40 per share, cut 25% of its workforce, and is launching a Phase 3 HCV trial while facing analyst skepticism over its drug.

Vandana Singh

ZBH Gears Up for Q3 Earnings: What Lies Ahead for the Stock?

Zimmer Biomet Holdings, Inc. (NYSE: ZBH) is scheduled to report third-quarter 2024 results on Oct. 30, before market open.

Zacks

PRO
Morgan Stanley Upgrades Atea Pharmaceuticals to Equal-Weight, Raises Price Target to $6.88

Morgan Stanley analyst Matthew Harrison upgrades Atea Pharmaceuticals (NASDAQ:AVIR) from Underweight to Equal-Weight and raises the price target from $2 to $6.88.

Benzinga Newsdesk

Atea Pharmaceuticals Inc

Atea Pharmaceuticals (AVIR) Stock Price Target 2026

The Average Analyst Price Target for Atea Pharmaceuticals is $8.50.

Latest Upgrades and Downgrades for Atea Pharmaceuticals Stock

Analyst Ratings News

PRO
Morgan Stanley Maintains Equal-Weight on Atea Pharmaceuticals, Raises Price Target to $7

PRO
Evercore ISI Group Maintains Outperform on Atea Pharmaceuticals, Raises Price Target to $10

PRO
Morgan Stanley Maintains Equal-Weight on Atea Pharmaceuticals, Lowers Price Target to $6

Atea Pharma Cuts Workforce By 25%, Expects $15 Million In Cost Savings, Plans Phase 3 Hepatitis C Trial

ZBH Gears Up for Q3 Earnings: What Lies Ahead for the Stock?

PRO
Morgan Stanley Upgrades Atea Pharmaceuticals to Equal-Weight, Raises Price Target to $6.88

People Also Watch

People Also Watch

Atea Pharmaceuticals Inc

Atea Pharmaceuticals (AVIR) Stock Price Target 2026

The Average Analyst Price Target for Atea Pharmaceuticals is $8.50.

Latest Upgrades and Downgrades for Atea Pharmaceuticals Stock

Analyst Ratings News

PROMorgan Stanley Maintains Equal-Weight on Atea Pharmaceuticals, Raises Price Target to $7

PROEvercore ISI Group Maintains Outperform on Atea Pharmaceuticals, Raises Price Target to $10

PROMorgan Stanley Maintains Equal-Weight on Atea Pharmaceuticals, Lowers Price Target to $6

Atea Pharma Cuts Workforce By 25%, Expects $15 Million In Cost Savings, Plans Phase 3 Hepatitis C Trial

ZBH Gears Up for Q3 Earnings: What Lies Ahead for the Stock?

PROMorgan Stanley Upgrades Atea Pharmaceuticals to Equal-Weight, Raises Price Target to $6.88

People Also Watch

People Also Watch

PRO
Morgan Stanley Maintains Equal-Weight on Atea Pharmaceuticals, Raises Price Target to $7

PRO
Evercore ISI Group Maintains Outperform on Atea Pharmaceuticals, Raises Price Target to $10

PRO
Morgan Stanley Maintains Equal-Weight on Atea Pharmaceuticals, Lowers Price Target to $6

PRO
Morgan Stanley Upgrades Atea Pharmaceuticals to Equal-Weight, Raises Price Target to $6.88